Get In Touch

Rotavirus, as the name suggests, is a kind of virus that readily infects children and infants. The virus can cause severe watery diarrhea, fever, vomiting, and abdominal pain. Rotavirus-infected children usually suffer from dehydration and in severe cases, they need to be hospitalized. Rotavirus vaccine is a highly successful method to protect children from rotavirus infection. Before the introduction of rotavirus vaccines in the market, rotavirus disease was a serious health issue among children in major developed and developing countries. For instance, in the U.S., almost all children have at least one rotavirus infection within the span of five years from birth; around 400,000 children are taken to doctors for treatment; and around 50–60 deaths occur every year. However, after the introduction of rotavirus vaccines, the number of emergency visits and hospitalizations due to rotavirus infection has dropped significantly. Four out of five children that are vaccinated get protection from severe rotavirus infection.

The global rotavirus vaccines market can be segmented based on product and distribution channel. Among products, two vaccines are licensed for use in the U.S. viz. RotaTeq (RV5) and Rotarix (RV1). RotaTeq is administered in three doses and Rotarix is administered in two doses at the interval of every two months. The first dose in administered after two months of birth. Currently, two key players operate in the rotavirus vaccines market, which are WHO-prequalified: Merck and GlaxoSmithKline (GSK). Two rotavirus vaccines currently being developed are expected to gain pre-qualification from the WHO between 2017 and 2018. One of these is Rotavac, which is being manufactured by Bharat Biotech. It was licensed for use in India in 2014. Based on distribution channel, the global rotavirus vaccines market can be classified into hospitals, pharmacies, and clinics / health care centers associated with government programs. The inflow of patients to hospitals is expected to increase during the forecast period, as hospitals are considered to be more reliable and they have a large number of suppliers, reimbursement authority, and government support.

Increasing incidence of rotavirus infection among children is a major factor that drives the market, as it leads to the rise in demand for rotavirus vaccines. Rotavirus disease is highly contagious and it spreads easily among children due to their poor hygiene habits. The spread of rotavirus infection is a common issue in hospitals and daycare settings. Along with this, support from organizations such as UNICEF and GAVI (is a vaccine alliance of multiple countries under which 45 countries are approved for Rotavirus vaccine support) for large scale vaccination, supply availability, and access to affordable prices is another factor fueling the rotavirus vaccines market. There are a few restrictions in delivering the rotavirus vaccines. For instance, a baby or infant who had a history of allergic reaction upon the administration of rotavirus vaccine should not be administered another dose. Also, diarrhea or vomiting caused by any other microorganism should not be treated with rotavirus vaccines. A virus named porcine circovirus is found in both rotavirus vaccines. Even though porcine circovirus does not have any harmful effect and there is no known safety risk, it is not preferred for critical patients. Moreover, delayed timelines for new manufacturers, delays in planned introductions, rising demand that exceeds the current supply, and uncertain demand from non-GAVI MICs are other factors that restrict the market for rotavirus vaccines.

Based on geography, the global rotavirus vaccines market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global rotavirus vaccines market, with the U.S. accounting for a major market share. Manufacturers in the Americas are developing innovative products to cure severe rotavirus infections among children. The safety and efficacy of these new products are being ensured by pre-market approval through clinical trials. Europe is considered the second-largest market for rotavirus vaccines. On the other hand, the market in Asia Pacific is expected to expand rapidly and at the maximum growth rate during the forecast period. This is attributable to rising government initiatives and favorable government laws in the region. Also, major manufacturers with their rotavirus vaccines currently undergoing development are located in Asia Pacific. For instance, Bharat Biotech International Limited, a manufacturer of Rotavac, is located in India and Lanzhou Institute of Biological Products that manufactures Lanzhou lamb rotavirus vaccine is located in China. Emerging countries with rapidly developing economies offer significant growth opportunities to the rotavirus vaccines market, as they witness the rising prevalence of rotavirus infection.

Key players in the global rotavirus vaccines market are GlaxoSmithKline (GSK), Merck, and Bharat Biotech International Limited. Other prominent bodies that are working on the development of rotavirus vaccines are Center for Research and Production of Vaccines, Vietnam and Lanzhou Institute of Biological Products, China.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Rotavirus Vaccines Market

Pre Book